Core Viewpoint - Chuangli Medical (01858) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong performance driven by stable supply of procurement products and expansion in international markets [1] Company Performance - Revenue for the first half of 2025 reached approximately 488 million yuan, representing a year-on-year growth of 28.27% [1] - Net profit attributable to shareholders was around 114 million yuan, showing a year-on-year increase of 44.85% [1] - The growth in revenue is attributed to stable supply of procurement products and continuous sales growth [1] - The increase in net profit is due to stable supply of procurement products, deepening international market expansion, and internal cost reduction efforts [1] Market Trends - Guojin Securities noted a recovery trend in domestic medical device procurement demand in the first half of 2025, with expectations for gradual performance recovery in the second half [1] - The demand for consumables is closely related to domestic patient treatment needs, showing relatively small overall fluctuations [1] - Leading medical device companies are accelerating their overseas market investments, with a noticeable increase in channel acquisitions in the first half of the year [1] - Many companies reported that their overseas market growth rates significantly outpaced domestic growth, with some leading firms seeing overseas revenue surpass domestic revenue [1]